Inhibition of Erbb2 by Trastuzumab Induces Oxidative Stress Markers in HER2 Positive Breast Cancer Cell Lines
Human epidermal growth factor receptor2 (HER2) amplification occurs in approximately 30% of breast cancers that associated with a faster rate of growth and a poorer prognosis. Trastuzumab is FDA-approved humanized monocholonal antibody that targets the extracellular domain of HER2. In present study...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Amber Publication
2018-03-01
|
Series: | Journal of Research in Medical and Dental Science |
Subjects: | |
Online Access: | https://www.jrmds.in/articles/inhibition-of-erbb2-by-trastuzumab-induces-oxidative-stress-markers-in-her2-positive-breast-cancer-cell-lines.pdf |